Fig. 5.
4.10-mAlb does not protect against experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA). a EAE was induced in male C57BL/6 mice, and clinical symptoms were scored in PBS (n = 6) or 4.10-mAlb (100 μg/mouse/day; n = 7) treated mice after immunization with MOG35–55 peptide. Average clinical scores are plotted ± SEM. b Arthritis was induced in 9- to10-week-old DBA/1 mice with chicken type-II collagen on days 0 and 21. Starting at day 20, mice were daily injected with 4.10-mAlb (100 μg/mouse/day; n = 16) or PBS (n = 16). Average clinical scores are plotted ± SEM. c On day 42, blood was collected and COMP serum levels determined. Bars represent average (n = 16) ±SEM. Results are representative for two independent experiments. Statistics: *P < 0.05 and **P < 0.001 Mann–Whitney U test